Real-time PCR inspection reduces costs and simplifies analysis procedures… Can select genes that influence the efficacy of new anticancer drugs for colon cancer

'U-TOP MSI Detection Kit', which allows you to easily check microsatellite instability (MSI), is recently released by the Ministry of Food and Drug Safety. It was announced on the 28th that it has obtained permission to manufacture in vitro diagnostic medical devices (Class 3).

Microsatellite (microsatellite) is part of a genome (DNA) in which a short nucleotide sequence consisting of 1 to 6 base pairs is repeated, and accounts for about 5% of all human DNA. When DNA is replicated, errors frequently occur in this section. If there is no protein that repairs the mismatch error or there is a problem with the function of correcting the replication error, the number of repetitions of the short nucleotide sequence is greater than normal and mutation may result.

Microsatellite instability refers to a condition in which the length of the repetitive sequence of the microsatellite is inconsistent and varied. If it is stable (MSI-H), it is called low-degree microsatellite instability (MSI-L) if it is one, and if it is negative, it is called microsatellite stability (MSS).

MSI is currently being used for auxiliary diagnosis of nasal polyposis colorectal cancer, and recently MSD's immune anticancer drug'Kitruda' (ingredient name pembrolizumab) is MSI-H from the US Food and Drug Administration (FDA). Regardless of carcinoma), this drug is emerging as an important biomarker with permission to prescribe it within the range of benefits. Kitruda is the world's first anticancer drug that can be used for specific gene mutations regardless of carcinoma.